{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:36:47Z","timestamp":1793277407865,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:00:00Z","timestamp":1793232000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shizuoka Prefecture","award":["Nothing"],"award-info":[{"award-number":["Nothing"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Health Popul Nutr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dyslipidaemia is a major risk factor for cardiovascular and cerebrovascular diseases; however, the optimal frequency of medical visits remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine whether medical visit frequency is associated with the incidence of cardiac events, cerebrovascular events, and mortality among patients initiating lipid-lowering therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using data from the Shizuoka Kokuho Database between April 1, 2012, and September 30, 2021. Patients initiating lipid-lowering therapy were classified into high-frequency (\u2265\u200922 visits in 2 years) and low-frequency (8\u201312 visits in 2 years) groups. After 1:3 propensity score matching and exclusion of patients with events within 2 years, 1,435 patients in the low-frequency group and 4,412 in the high-frequency group were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a mean follow-up of 5.3 years, composite outcomes occurred in 5.6% of both groups (hazard ratio [HR] 1.08; 95% confidence interval [CI] 0.84\u20131.38;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.571). No significant differences were observed for cardiac events (HR 1.13; 95% CI 0.83\u20131.54), cerebrovascular events (HR 1.13; 95% CI 0.67\u20131.90), or mortality (HR 0.94; 95% CI 0.60\u20131.48).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Less frequent visits were not associated with increased risks of cardiovascular events or mortality. Extending visit intervals may therefore be a reasonable option for selected stable patients receiving lipid-lowering therapy for primary prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41043-026-01408-5","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T11:24:05Z","timestamp":1785669845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of medical visit frequency with cardiovascular events and mortality in patients with dyslipidaemia: a cohort study using a Japanese claims database"],"prefix":"10.1186","volume":"45","author":[{"given":"Taku","family":"Matsunaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-446X","authenticated-orcid":false,"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,2]]},"reference":[{"key":"1408_CR1","doi-asserted-by":"publisher","first-page":"101819","DOI":"10.1016\/j.pmedr.2022.101819","volume":"27","author":"N Thongtang","year":"2022","unstructured":"Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Prev Med Rep. 2022;27:101819.","journal-title":"Prev Med Rep"},{"issue":"2","key":"1408_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4330\/wjc.v8.i2.201","volume":"8","author":"AD Hendrani","year":"2016","unstructured":"Hendrani AD, Adesiyun T, Quispe R, et al. Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World J Cardiol. 2016;8(2):201\u201310.","journal-title":"World J Cardiol"},{"issue":"42","key":"1408_CR3","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359\u201378.","journal-title":"Eur Heart J"},{"issue":"23","key":"1408_CR4","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J"},{"issue":"10440","key":"1408_CR5","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100\u201332.","journal-title":"Lancet"},{"issue":"1","key":"1408_CR6","doi-asserted-by":"publisher","first-page":"e0280311","DOI":"10.1371\/journal.pone.0280311","volume":"18","author":"K Hirata","year":"2023","unstructured":"Hirata K, Matsumoto K, Hatakeyama Y, Onishi R, Seto K, Hasegawa T. Social burden of three major diseases in Japan: A time trend and future projections using the comprehensive cost of illness method. PLoS ONE. 2023;18(1):e0280311.","journal-title":"PLoS ONE"},{"issue":"8","key":"1408_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2022.12138","volume":"328","author":"R Chou","year":"2022","unstructured":"Chou R, Cantor A, Dana T, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022;328(8):754\u201371.","journal-title":"JAMA"},{"issue":"25 Pt B","key":"1408_CR8","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"key":"1408_CR9","unstructured":"OECD. Health at a Glance 2023. Accessed June 23. 2025. https:\/\/www.oecd-ilibrary.org\/social-issues-migration-health\/health-at-a-glance-2023_7a7afb35-en"},{"key":"1408_CR10","unstructured":"Ministry of Health, Labour and Welfare. Trends in Dispensing Medical Expenses (Computerized Processing). 2023. September 1, 2023. Accessed June 23, 2025. https:\/\/www.mhlw.go.jp\/content\/001296971.pdf"},{"issue":"1","key":"1408_CR11","first-page":"35","volume":"39","author":"NK Ayumi Maeda","year":"2020","unstructured":"Ayumi Maeda NK. Estimating Economic Effects of Instituting a Refill Prescription System in Japan. Japanese J Social Pharm. 2020;39(1):35\u20139.","journal-title":"Japanese J Social Pharm"},{"issue":"7","key":"1408_CR12","doi-asserted-by":"publisher","first-page":"e0254631","DOI":"10.1371\/journal.pone.0254631","volume":"16","author":"P Ferrara","year":"2021","unstructured":"Ferrara P, Di Laura D, Cortesi PA, Mantovani LG. The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies. PLoS ONE. 2021;16(7):e0254631.","journal-title":"PLoS ONE"},{"issue":"8","key":"1408_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"1408_CR14","doi-asserted-by":"publisher","first-page":"e10743","DOI":"10.1002\/jbm4.10743","volume":"7","author":"E Ohata","year":"2023","unstructured":"Ohata E, Nakatani E, Kaneda H, Fujimoto Y, Tanaka K, Takagi A. Use of the Shizuoka Hip Fracture Prognostic Score (SHiPS) to Predict Long-Term Mortality in Patients With Hip Fracture in Japan: A Cohort Study Using the Shizuoka Kokuho Database. JBMR Plus. 2023;7(6):e10743.","journal-title":"JBMR Plus"},{"key":"1408_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jdin.2023.04.007","volume":"12","author":"H Hashizume","year":"2023","unstructured":"Hashizume H, Nakatani E, Sasaki H, Miyachi Y. Hydrochlorothiazide increases risk of nonmelanoma skin cancer in an elderly Japanese cohort with hypertension: The Shizuoka study. JAAD Int. 2023;12:49\u201357.","journal-title":"JAAD Int"},{"issue":"3","key":"1408_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.5551\/jat.61960","volume":"29","author":"T Honda","year":"2022","unstructured":"Honda T, Chen S, Hata J, et al. Development and Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Disease in Japanese Adults: The Hisayama Study. J Atheroscler Thromb. 2022;29(3):345\u201361.","journal-title":"J Atheroscler Thromb"},{"key":"1408_CR17","doi-asserted-by":"publisher","unstructured":"Okamura T, Tsukamoto K, Arai H, et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb Published online Dec. 2023;19. https:\/\/doi.org\/10.5551\/jat.GL2022.","DOI":"10.5551\/jat.GL2022"},{"issue":"3","key":"1408_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141\u201354.","journal-title":"Ann Stat"},{"issue":"3","key":"1408_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"1408_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2188\/jea.JE20200480","volume":"32","author":"E Nakatani","year":"2022","unstructured":"Nakatani E, Tabara Y, Sato Y, Tsuchiya A, Miyachi Y. Data Resource Profile of Shizuoka Kokuho Database (SKDB) Using Integrated Health- and Care-insurance Claims and Health Checkups: The Shizuoka Study. J Epidemiol. 2022;32(8):391\u2013400.","journal-title":"J Epidemiol"},{"issue":"5","key":"1408_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/hr.2015.157","volume":"39","author":"A Shima","year":"2016","unstructured":"Shima A, Tatsumi Y, Ishizaki T, et al. Relationship between outpatient visit frequency and hypertension control: a 9-year occupational cohort study. Hypertens Res. 2016;39(5):376\u201381.","journal-title":"Hypertens Res"},{"issue":"6","key":"1408_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1524-6175.2005.04371.x","volume":"7","author":"R Guthmann","year":"2005","unstructured":"Guthmann R, Davis N, Brown M, Elizondo J. Visit frequency and hypertension. J Clin Hypertens. 2005;7(6):327\u201332.","journal-title":"J Clin Hypertens"},{"issue":"8","key":"1408_CR23","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/jch.14698","volume":"25","author":"D Kim","year":"2023","unstructured":"Kim D, Jeong H, Kim S, et al. Association between office visit intervals and long-term cardiovascular risk in hypertensive patients. J Clin Hypertens. 2023;25(8):748\u201356.","journal-title":"J Clin Hypertens"},{"issue":"5","key":"1408_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/jgf2.252","volume":"20","author":"D Kato","year":"2019","unstructured":"Kato D, Ryu H, Matsumoto T, et al. Building primary care in Japan: Literature review. J Gen Fam Med. 2019;20(5):170\u20139.","journal-title":"J Gen Fam Med"},{"issue":"10440","key":"1408_CR25","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(24)00476-8","volume":"403","author":"GBD 2021 Demographics Collaborators","year":"2024","unstructured":"GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):1989\u20132056.","journal-title":"Lancet"},{"issue":"12","key":"1408_CR26","doi-asserted-by":"publisher","first-page":"e0295052","DOI":"10.1371\/journal.pone.0295052","volume":"18","author":"D Funaki","year":"2023","unstructured":"Funaki D, Kaneda H, Miyakoshi A, Saito K, Sasaki H, Nakatani E. Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality. PLoS ONE. 2023;18(12):e0295052.","journal-title":"PLoS ONE"},{"issue":"4","key":"1408_CR27","first-page":"402","volume":"60","author":"T Uto","year":"2024","unstructured":"Uto T, Yasutaka Y, Hamabashiri M, Kaneshige S, Kamimura H. A Survey on the Current Status of Refill Prescriptions and Its Impact on Hospital Management. J Japanese Soc Hosp Pharmacists. 2024;60(4):402\u20137.","journal-title":"J Japanese Soc Hosp Pharmacists"},{"issue":"3\u20134","key":"1408_CR28","first-page":"53","volume":"105","author":"S Katsushi Fukuoka","year":"2024","unstructured":"Katsushi Fukuoka S, Yuge Y, Hayashi. Mitsuo Saito. Trends in Refill Prescriptions in the Kanto Region. Oyo Yakuri. 2024;105(3\u20134):53\u20136.","journal-title":"Oyo Yakuri"},{"issue":"1","key":"1408_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3122\/jabfm.19.1.31","volume":"19","author":"CW Ferrell","year":"2006","unstructured":"Ferrell CW, Aspy CB, Mold JW. Management of prescription refills in primary care: an Oklahoma Physicians Resource\/Research Network (OKPRN) study. J Am Board Fam Med. 2006;19(1):31\u20138.","journal-title":"J Am Board Fam Med"},{"key":"1408_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.22454\/PRiMER.2023.418724","volume":"7","author":"S Khan","year":"2023","unstructured":"Khan S, Kram JJF, Baumgardner DJ, et al. Implementation of a Multidisciplinary Medication Refill Protocol. PRiMER. 2023;7:31.","journal-title":"PRiMER"},{"issue":"9753","key":"1408_CR31","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"}],"container-title":["Journal of Health, Population and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41043-026-01408-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41043-026-01408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41043-026-01408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:09:04Z","timestamp":1793275744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41043-026-01408-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1186\/s41043-026-01408-5","relation":{},"ISSN":["2072-1315"],"issn-type":[{"value":"2072-1315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of the Graduate School of Public Health, Shizuoka Graduate University of Public Health, Japan (SGUPH_2021_001_074\u2009\u2212\u20092).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"241"}}